With the U.S. Supreme Court’s denial of certiorari in Purdue Pharma L.P. v. Accord Healthcare, Inc. (No. 24-1132), the Federal Circuit’s decision (No. 2023-1953, Dec. 30, 2024) now stands as controlling authority on the nexus requirement for objective indicia of non-obviousness. This CLE program takes a detailed look at Purdue’s litigation strategy from trial through appeal, unpacking how the company approached arguments on obviousness and secondary considerations.

The discussion also explores how the Federal Circuit’s reasoning refines the evidentiary standards for demonstrating non-obviousness and what this means for future patent prosecution and litigation. Attendees will come away with practical insights for strengthening client advocacy and aligning legal strategy with evolving patent jurisprudence.